Abbott Laboratories' medical device business is executing well, with double-digit growth in structural heart and diabetes.

The decision to allow a new trial could have  implications for both the companies and families with babies born prematurely.

Shares of Abbott Laboratories ABT slid 3.42% to $132.66 Tuesday, on what proved to be an all-around rough trading session for ...

Infant formula makers Abbott and Reckitt saw their stocks decline Friday after a judge ruled plaintiffs could pursue a new ...

Abbott Laboratories is undervalued with strong growth in diabetes care and weight-loss markets. Discover why ABT stock is a ...

In the last year, many Abbott Laboratories ( NYSE:ABT ) insiders sold a substantial stake in the company which may ...

ABT's shares rise on the back of its diversified business portfolio. However, the unfavorable macroeconomic scenario is concerning.

This was the stock's second consecutive day of losses.

Whales with a lot of money to spend have taken a noticeably bullish stance on Abbott Laboratories. If we consider the ...

Mead Johnson and Abbott Laboratories are to face a new trial in the US over allegations their premature infant formula can ...

Analysts have recently evaluated Abbott Laboratories and provided 12-month price targets. The average target is $145.12, ...

Abbott Laboratories and Reckitt Benckiser Group Plc shares fell as a judge ordered a new trial after rejecting a verdict that ...